---
company: Century Therapeutics, Inc.
ticker: IPSC
form: 8-K
filed: 2026-08-12
accession: 0001104659-26-094533
source: https://www.sec.gov/Archives/edgar/data/1850119/000110465926094533/
---

# Century Therapeutics (IPSC) earnings release, August 12, 2026

Century Therapeutics, Inc. (IPSC) · Form 8-K, Item 2.02 · Filed 2026-08-12 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1850119/000110465926094533/)

Century Therapeutics Reports Second Quarter 2026 Financial

Results and Business Updates

PHILADELPHIA, August 12, 2026 –– Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell

(iPSC)-derived cell therapies for autoimmune diseases, including T1D, and cancer, today reported financial results for the second quarter ended June 30, 2026, and recent business highlights.

"We are executing with speed against key development milestones, reinforcing our confidence in delivering on our ambition to transform diseases like T1D by creating functional cures at scale," said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics. "With CNTY-813, our preclinical data at ADA

2026 continue to support its potential as a functional T1D cure, and we have established our Phase 1 manufacturing process, demonstrating consistent product quality across independent batches. Our recent pre-IND meeting with the FDA builds on that progress yielding alignment with the FDA on our nonclinical data package, manufacturing strategy, and proposed Phase 1/2 trial design, keeping CNTY-813's IND submission on track for the fourth quarter of 2026. In addition, CNTY-308 remains on track to enter the clinic in 2026."

Second Quarter 2026 and Recent Highlights

Pre-IND meeting with the FDA supports regulatory and initial clinical path for CNTY-813

Data demonstrated key advancements for CNTY-813 including:

CNTY-813 Phase 1 manufacturing process established

CNTY-813 preclinical data selected for oral presentations at congresses this fall

CNTY

-

308 clinical trial planned to initiate in 2026

Second Quarter 2026 Financial Results

About Century Therapeutics

Century Therapeutics (NASDAQ: IPSC) is a biotechnology company advancing a pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies with the potential to meaningfully address autoimmune diseases, including type 1 diabetes, and cancer. Century’s therapies are derived from its iPSC cell foundry and leverage its novel immune evasion engineering technology, Allo-Evasion™. Century believes its approach to developing off-the-shelf cell therapies will expand patient access and provide advantages over existing cell therapies which will ultimately advance the course of care. For more information on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements our timing and expectations regarding our preclinical and clinical development programs, including their planned development, therapeutic potential and market opportunity, ongoing and planned regulatory submissions and interactions, the achievement of developmental milestones, corporate strategies, anticipated data readouts, and our financial resources and expected cash runway are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,”

“might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,”

“anticipate,” “could,” “intend,” “target,” “project,” “contemplate,”

“believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions.

We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our ability to meet development milestones on anticipated timelines; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials, which may not be predictive of final results or the results of later-stage clinical trials; our ability to obtain clearance of our future

IND or CTA submissions and commence and complete clinical trials on expected timelines, or at all; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of geopolitical issues, trade disputes and tariffs, banking instability and inflation on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales... (truncated)ility to recruit and maintain key members of management and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements.

Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

For More Information:

Century Therapeutics

Douglas Carr

Senior Vice President, Finance investor.relations@centurytx.com

Corey Davis, Ph.D.

LifeSci Advisors,

LLC 212-915-2577 cdavis@lifesciadvisors.com

Century

Therapeutics,

Inc.

Condensed

Balance Sheets

(unaudited, in thousands)

Century

Therapeutics,

Inc.

Condensed consolidated statements of operations

(unaudited, in thousands, except share and per share amounts)

## Financial statements

### Income Statement (Three Months Ended — (unaudited, in thousands, except share and per share amounts))

| | Three Months Ended – June 30, 2026 | Three Months Ended – June 30, 2025 | Six Months Ended – June 30, 2026 | Six Months Ended – June 30, 2025 |
|---|---:|---:|---:|---:|
| Collaboration revenue | $— | $— | $— | 109,164 |
| Operating expenses | Research and development | 19,595 | 26,859 | 36,700 | 53,439 |
| Operating expenses | General and administrative | 5,787 | 7,805 | 12,366 | 16,212 |
| Operating expenses | Loss on lease component termination | 11,145 |  | 11,145 |  |
| Operating expenses | Total operating expenses | 36,527 | 34,664 | 60,211 | 69,651 |
| Operating expenses | Income (loss) from operations | -36,527 | -34,664 | -60,221 | 39,513 |
| Operating expenses | Interest income | 1,982 | 2,010 | 4,001 | 4,431 |
| Operating expenses | Other income (expense), net | -5 | 113 | 15 | 75 |
| Operating expenses | Total other income | 1,977 | 2,123 | 4,016 | 4,506 |
| Operating expenses | Net income (loss) | -34,550 | -32,541 | -56,195 | 44,019 |
| Operating expenses | Unrealized loss on investments | -109 | -222 | -724 | -241 |
| Operating expenses | Comprehensive income (loss) | -34,659 | -32,763 | -56,919 | 43,778 |
| Operating expenses | Net income (loss) per common share, basic and diluted | -0.17 | -0.38 | -0.28 | 0.51 |
| Operating expenses | Weighted average common shares outstanding, basic | 205,778,156 | 86,238,084 | 199,660,522 | 86,130,235 |
| Operating expenses | Weighted average common shares outstanding, diluted | 205,778,156 | 86,238,084 | 199,660,522 | 86,207,666 |

### Balance Sheet (June 30, 2026 — (unaudited, in thousands))

| | June 30, 2026 | December 31, 2025 |
|---|---:|---:|
| Current assets | Cash and cash equivalents | 49,642 | 61,853 |
| Current assets | Short-term investments | 70,070 | 55,261 |
| Current assets | Prepaid expenses and other current assets | 5,056 | 3,655 |
| Current assets | Total current assets | 124,768 | 120,769 |
| Current assets | Property and equipment, net | 34,482 | 50,026 |
| Current assets | Operating lease right-of-use assets | 13,513 | 16,139 |
| Current assets | Long-term investments | 77,477 |  |
| Current assets | Intangible assets | 34,200 | 34,200 |
| Current assets | Other long-term assets | 2,566 | 2,570 |
| Current assets | Total assets | 287,006 | 223,704 |
| Current liabilities | Accounts payable | 4,823 | 4,773 |
| Current liabilities | Accrued expenses and other liabilities | 10,245 | 11,696 |
| Current liabilities | Contingent consideration liability, short-term |  | 3,757 |
| Current liabilities | Total current liabilities | 15,068 | 20,226 |
| Current liabilities | Operating lease liability, long term | 34,626 | 40,241 |
| Current liabilities | Other long-term liabilities | 666 |  |
| Current liabilities | Deferred tax liability | 4,301 | 4,301 |
| Current liabilities | Total liabilities | 54,661 | 64,768 |
| Current liabilities | Common stock | 18 | 9 |
| Current liabilities | Additional paid-in capital | 1,081,133 | 950,814 |
| Current liabilities | Accumulated deficit | -848,112 | -791,917 |
| Current liabilities | Accumulated other comprehensive income | -694 | 30 |
| Current liabilities | Total stockholders’ equity | 232,345 | 158,936 |
| Current liabilities | Total liabilities and stockholders’ equity | 287,006 | 223,704 |
